
GSK3145095
CAS No. 1622849-43-7
GSK3145095( —— )
Catalog No. M22000 CAS No. 1622849-43-7
GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 133 | In Stock |
![]() ![]() |
5MG | 259 | In Stock |
![]() ![]() |
10MG | 441 | In Stock |
![]() ![]() |
25MG | 705 | In Stock |
![]() ![]() |
50MG | 981 | In Stock |
![]() ![]() |
100MG | 1332 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameGSK3145095
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
-
DescriptionGSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic. GSK3145095 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses.?Highlighting its potential as a novel cancer therapy, the inhibitor was also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures.?(In Vitro):GSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC50 = 1.6 nM), cell death as measured by LDH release (IC50 = 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1β production, either as absolute levels for protein, or fold changes in mRNA expression (IC50 = 0.4 nM) .
-
In VitroGSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC50 = 1.6 nM), cell death as measured by LDH release (IC50 = 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1β production, either as absolute levels for protein, or fold changes in mRNA expression (IC50 = 0.4 nM) .
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorRIP1
-
Research AreaEndocrine system;Cancer
-
IndicationNeoplasms, Pancreatic
Chemical Information
-
CAS Number1622849-43-7
-
Formula Weight397.38
-
Molecular FormulaC20H17F2N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:245mg/ml (616.54 Mm; Need ultrasonic)
-
SMILESFC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NNC(CC3=CC=CC=C3)=N2)C(F)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Harris PA, ET AL. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
molnova catalog



related products
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.
-
Cucurbitacin IIA
Cucurbitacin IIA can induce apoptosis and enhance autophagy, contributes to the anti-inflammatory activity of Cucurbitacin IIA against inflammation-related diseases.
-
Certolizumab pegol
Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).